Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was presented during a Late Breaker session at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC Virtual). The pooled analysis of the ORION-9, -10 and -11 Phase III trials ...

Sign up today to gain access to 5 free articles a month from over 200 top subscription outlets.

Are you ready to take your business development to the next level with RelSci Professional?

Nurture your network with daily alerts that notify you when your relationships make news

Map your relationships to any target or prospect to identify a warm introduction

Access unlimited deep dossiers on over 8 million decision makers

Best of all, you can try out all these powerful business development tools absolutely free for 30 days!

Check out News Home to stay on top of the people and organizations you care most about.